论文部分内容阅读
目的初步探索Firehawk雷帕霉素药物洗脱支架在临床应用中的效益分析。方法回顾2015年1月至2015年12月期间分别接受Firehawk支架及Fierbird2支架介入治疗的89例冠心病患者,通过分析对比一般情况、介入相关情况及随访相关指标,初步探索Firehawk雷帕霉素药物洗脱支架在临床应用中的安全性及疗效。结果两组在支架直径、支架长度及支架释放压力方面均无统计学差异(P>0.05),而Firehawk组支架数低于Firebird2组(P<0.05);两组随访期间均无全因死亡、心脏性死亡、急性心梗及主要不良心脏事件发生;复查造影者亦均无支架内再狭窄、靶病变血运重建及晚期血栓形成;两组造影复查率均较高且无统计学差异(P>0.05);两组均有再发心绞痛病例,Firehawk组较Firebird2组无统计学差异(P>0.05);两组在随访时间(月)方面有统计学差异(P<0.05),其中Firehawk组低于Firebird2组。结论 Firehawk支架在冠脉介入治疗中安全有效。
Objective To explore the benefit analysis of the Firehawk rapamycin-eluting stent in clinical application. Methods From January 2015 to December 2015, 89 patients with CHD treated with Firehawk stent and Fierbird2 stent respectively were retrospectively analyzed. Based on the analysis of general conditions, interventional related factors and follow-up related indexes, we initially explored the effects of Firehawk rapamycin Efficacy and safety of eluting stents in clinical application. Results There was no significant difference in stent diameter, stent length and stent release pressure between the two groups (P> 0.05), while the Firehawk stent group was lower than Firebird2 group (P <0.05) Cardiac death, acute myocardial infarction and major adverse cardiac events occurred. There were no in-stent restenosis, target revascularization and advanced thrombosis in the repeat angiogram. The rate of angiography examination was higher in both groups (P > 0.05). There were no recurrences of angina in both groups, and no significant difference was found between Firehawk group and Firebird 2 group (P> 0.05). There was a significant difference in the follow-up time (month) between the two groups (P <0.05) Lower than Firebird2 group. Conclusion Firehawk stent is safe and effective in coronary intervention.